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Urinary chromium is associated with changes in leukocyte
miRNA expression in obese subjects
L Dioni1, S Sucato1, V Motta1, S Iodice1, L Angelici1, C Favero1, T Cavalleri2, L Vigna3, B Albetti1, S Fustinoni1,3, P Bertazzi1,3,
A Pesatori1,3 and V Bollati1,3
BACKGROUND/OBJECTIVES: Epidemiological studies suggest a link between chromium (Cr) status and cardiovascular disease.
Increased urinary excretion of Cr was reported in subjects with diabetes compared with non-diabetic controls and those with non-
diabetic insulin resistance. Epigenetic alterations have been linked to the presence of Cr, and microRNA (miRNA) expression has
been implicated in the pathogenesis of metabolic diseases and cardiovascular diseases (CVDs). We investigated the association
between Cr excretion and miRNA expression in leukocytes from obese subjects. We also examined the relationship between altered
miRNA expression and selected clinical parameters to further investigate mechanisms linking Cr to metabolic diseases and CVDs.
SUBJECTS/METHODS: We analyzed urinary Cr in 90 Italian subjects using inductively coupled plasma-mass spectrometry.
Peripheral blood miRNA levels were screened with TaqMan Low-Density Array Human MicroRNA A. Cr level-associated expression
of miRNAs was detected with multivariate regression analyses, and the top 10 candidate miRNAs were selected for validation. We
also used multivariate regression analyses to assess possible associations between validated miRNAs and glycated hemoglobin
(A1c) and blood pressure (BP). The validated miRNAs were further investigated by functional analysis with Ingenuity Pathway
Analysis software.
RESULTS: Urinary Cr levels (mean: 0.35 μg/l; s.d. = 0.24) ranged from 0.05 to 1.27 μg/l. In the screening phase, 43 miRNAs were
negatively associated with Cr. Of the top 10 miRNAs selected for validation, nine (miR-451, miR-301, miR-15b, miR-21, miR-26a,
miR-362-3p, miR-182, miR-183 and miR-486-3p) were downregulated in association with Cr (P-false discovery rate (FDR)o0.10).
miR-451 expression was associated with A1c (β= –0.06; P= 0.0416), whereas miR-486-3p expression was associated both with
diastolic (β= 2.1; P= 0.004) and systolic BP (β= 3.3; P= 0.003).
CONCLUSIONS: These results indicate that miR-451 and miR-486-3p are involved in the link between Cr levels and metabolic
diseases and CVDs.
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INTRODUCTION
Chromium (Cr) is the sixth most abundant element in the earth’s
crust and seawater, existing in several oxidation states, principally
metallic, trivalent and hexavalent Cr. Trivalent Cr, an essential trace
element for humans, is a critical cofactor for insulin1 and has a
well-documented role in maintaining normal glucose tolerance.2–4
Dietary Cr is available in drinking water and various foods,
including meats, whole-grains, some fruits, vegetables and spices.5
The recommended daily dietary Cr intake for healthy adults is
24–35 μg from age 14 to 50 years and 20–30 μg after 50 years of
age.6 Once adsorbed into the blood, Cr is widely distributed, but is
most concentrated in the kidneys, muscles and liver.7 Cr effects
are dependent upon the form and amount of supplemental Cr
Excretion of absorbed Cr occurs primarily via urine.8 Higher than
normal urinary Cr excretion has been reported for diabetics9 and
non-diabetic insulin-resistant patients.10,11 Epidemiological studies
have suggested that Cr status may be linked with cardiovascular
diseases (CVDs).12,13
Epigenetic alterations, such as DNA methylation, posttransla-
tional histone modiﬁcations and alterations of small non-coding
RNAs, are linked to the presence of Cr in organisms14 and regulate
homeostatic and inducible gene expression.15 MicroRNAs (miR-
NAs) are non-coding, small, single-stranded RNAs approximately
21–25 nucleotides long that have important regulatory roles in
gene expression. They downregulate expression of target genes at
the posttranscriptional level by binding to the 3’ untranslated
regions of target mRNAs.16 Aberrant miRNA expression has been
implicated in several metabolic processes, including energy and
lipid metabolism, which have been studied in the context of
diabetes,17 insulin resistance18 and CVD.19
Obesity, deﬁned as a body mass index (BMI) of 30 kg/m2 or
greater, is strongly associated with onset of type 2 diabetes,20,21
insulin resistance 22 and CVD.23 Therefore, obese individuals may
represent a suitable population to investigate the epigenetic
mechanisms linking Cr levels with metabolic diseases and CVDs.
The glycated hemoglobin (A1c) value is an integrated measure of
mean glucose levels over time and is considered the ‘gold standard’
for monitoring metabolic control in patients with insulin resistance
and diabetes.24 Elevated blood pressure (BP) is a well-established
risk factor for CVD; an increase in systolic BP of 1 mm Hg has been
estimated to raise the risk of death due to CVD by 2–4%.25
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This study aimed to verify a possible association between
urinary Cr levels and miRNA expression in leukocytes from obese
subjects. In addition, we sought to examine the relationship
between altered miRNA expression and two clinical parameters,
A1c and diastolic/systolic BP, to further investigate mechanisms
linking Cr to metabolic diseases and CVDs.
MATERIALS AND METHODS
Study design
Ninety subjects were recruited from the ‘Center for Obesity and Weight
Control’ at ‘Ospedale Maggiore Policlinico, Fondazione IRCCS Ca’ Granda’
in Milan, Italy. The study subjects were a subgroup of the SPHERE
(‘Susceptibility to Particle Health Effects, miRNA, and Exosomes’) project,
funded by ERC-2011-StG (282413) to examine molecular mechanisms
underlying the effects of particulate matter and metal exposure on health
outcomes. Detailed information on this population has been reported
previously.26 Each study participant provided written informed consent in
compliance with the ethics committee of the ‘Ospedale Maggiore
Policlinico’ (approval number 1425) and donated 15 ml of blood and
50 ml of urine. A lifestyle questionnaire collecting information on
sociodemographic data, residence, education, smoking history, eating
habits, personal and family medical history, medication used in the last
year, and physical activity was administered to each participant. The
lifestyle questionnaire is a short version of the questionnaire used in the
EAGLE study (environment and genetics in lung cancer etiology, a
population-based case–control study, http://eagle.cancer.gov) and details
about information collected in it can be found in our previous article.26 The
questionnaire is checked for completeness at the time of data collection in
order to ensure high-quality data.
Urine sampling and Cr analysis
Urine samples were collected in polyethylene tubes and delivered to the
laboratory at room temperature within 2 h after collection; 5 ml aliquots
were stored at –20 °C until analysis, which occurred within 12 months after
collection. Before analysis, samples were thawed at room temperature,
then mixed and heated for 30 min at 37 °C to dissolve the sediment. One
milliliter of urine was diluted with 4 ml aqueous nitric acid, 0.05% v/v (from
ultrapure nitric acid 67%, Merck, Darmstadt, Germany), containing the
stock solution IV-ICP-MS-71D with standards (Inorganic Ventures, Chris-
tiansburg, VA, USA). All solutions were prepared using Milli-Q ultrapure
water (conductivity 0.056 μS/cm) (Merck). Samples were subjected to
inductively coupled plasma-mass spectrometry (ICP-MS) with an ICP-MS X
Series II machine (Thermo Scientiﬁc, Rodano, Italy) using the kinetic energy
discrimination mode to reduce interferences, operating with H2 in He (8%
v/v) as the collision and reaction gas. The instrument was supplied with
standard Ni/Cu cones, a quartz injector (1.5 mm oriﬁce), and a cyclonic
spray chamber, and was operated using Ar with a nebulized gas ﬂow of
0.91 l/min, an auxiliary gas ﬂow of 0.6 l/min and a cool gas ﬂow of 13 l/min.
Ions m/z 52 and 89 for Cr and yttrium as the analytic and internal
standards, respectively, were acquired with a dwell time of 10 ms.
Quantiﬁcation was performed using a calibration curve obtained with
aqueous solutions containing Cr in concentrations ranging from 0.05 to
2.5 μg/l. The detection limit of the assay was 0.03 μg/l, with a
quantiﬁcation limit of 0.05 μg/l; the assay accuracy was 97–102% and its
precision 2.5–5.9%. Internal quality control was performed using Lypho-
chek Urine Metals Control, level-1 and level-2 (Bio-Rad Laboratories,
Segrate, Italy), and Seronorm Level-1 (Sero AS, Billingstad, Norway).
Blood collection and RNA isolation
Peripheral blood samples were collected in PAXgene Blood RNA tubes,
sent immediately to the laboratory and, after 24 h, frozen at –80 °C,
according to manufacturer’s instructions. PAX tubes were chosen for RNA
collection because they contain a solution that inhibits RNA degradation
and gene induction as blood is drawn into the tube. Total RNA was
extracted from whole blood with MagMAX-96 according to the
manufacturer’s protocols (Ambion, Austin, TX, USA). RNA was quantiﬁed
using a ND-1000 Spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE, USA).
Screening of miRNA expression
Reverse transcription (RT) was performed using the TaqMan MicroRNA
Reverse Transcription Kit and Megaplex RT Primers A, following the
manufacturer’s instructions (Life Technologies, Carlsbad, CA, USA). Brieﬂy,
3 μl of RNA (110 ng) from blood were added to 4.5 μl of the RT reaction
mixture, which included 0.8 μl Megaplex RT Primer Pools A (10 × ), 0.2 μl
dNTPs (100 nM), 1.5 μl MultiScribe Reverse Transcriptase (50 U/μl), 0.8 μl RT
Buffer (10 × ), 0.9 μl MgCl2 (25 mM), 0.1 μl RNase inhibitor (20 U/μl) and
0.2 μl nuclease-free water. After incubation on ice for 5 min, RT was
performed using a C1000 Thermal Cycler (Bio-Rad, Hercules, CA, USA).
Thermal cycler conditions were as follows: 40 cycles of 16 °C for 2 min,
42 °C for 1 min and 50 °C for 1 s, followed by one step of 85 °C for 5 min.
The RT reaction was stored at –20 °C and used within 1 month.
For each sample, miRNA proﬁling was performed with a TaqMan Low-
Density Array (TLDA - TaqMan Array Human MicroRNA A Cards Set v2.1;
Life Technologies), pre-loaded 384-well microﬂuidic cards, with 384
spotted assays including 377 human miRNAs selected for their biological
functions and relationships, three endogenous small RNA human controls
(RNU6, RNU44 and RNU48, the ﬁrst being in quadruplicate), and a non-
human negative control (Ath-miR159a). All reactions were performed as
speciﬁed in the manufacturers’ protocols. Brieﬂy, a total reaction mixture
containing RT products and TaqMan Universal PCR Master Mix (Life
Technologies) was added to each TLDA line after gentle vortex mixing, and
then each card was centrifuged and sealed mechanically with a Life
Technologies sealing device. TLDAs were performed with the 7900HT Fast
Real-Time PCR System (Life Technologies), and the thermal cycler
conditions were as follows: 50 °C for 2 min, 94.5 °C for 10 min, and then
40 cycles of 97 °C for 30 s and 59.7 °C for 1 min. Gene Expression Suite
Software (Life Technologies) was used to process miRNA expression data
from TLDA, using automatic baseline settings and a threshold of 0.2.
Validation of miRNA expression
Validation of previous ﬁndings was performed using the custom TLDA
including the following TaqMan miRNA assays: miR-15b, miR-21, miR-26a,
miR-101, miR-182, miR-183, miR-301a, miR-362-3p, miR-451, miR-486-3p,
RNU6, RNU44 and RNU48. Using the custom RT primer pool, 3 μl of RNA
(110 ng) were RT. The 12- μl RT reaction mix included: 6 μl Custom RT
primer Pool, 0.3 μl dNTPs (100 nM), 3 μl MultiScribe RT (50 U/μl), 1.5 μl
RT Buffer (10 × ), 0.19 μl RNase inhibitor (20 U/μl) and 1.01 μl nuclease-free
water. After incubation on ice for 5 min, RT was performed using a C1000
Thermal Cycler (Bio-Rad). Thermal cycler conditions were as follows: one
step of 16 °C for 30 min, one step of 42 °C for 30 min, followed by one step
of 85 °C for 5 min. The RT reaction was stored at –20 °C and used within
one month. All TLDA reactions were performed using 7900HT Fast Real-
Time PCR System (Life Technologies), as speciﬁed in the protocols of the
manufacturer, and each assay was run in triplicate. Furthermore, one no-RT
control and one no-template control were carried in the ﬁrst custom TLDA.
The no-RT control experiment was performed with RNase-free water
instead of RT to test for the presence of genomic DNA, and the no-
template control experiment was performed with RNase-free water instead
of RT product to test for primer–dimer formation. As these controls were
negative, all samples were analyzed.
miRNA expression data analysis
Real-time PCR permitted quantitative measurement, expressed as related
cycle threshold (Ct) of miRNA expression.27 Ct is the number of PCR cycles
at which the efﬁciency of the real-time PCR reaction is maximal for each
miRNA target. In the screening phase, the starting point was a data set
containing, for each subject, the Ct values of 377 miRNAs and an
AmpScore value, which is a quality index, ranging from 0 to 2, which
indicates ampliﬁcation curve quality in the linear phase.
We applied an automatic miRNA selection, setting the values of miRNAs
with CtX 33 and/or with AmpScorep 1, and/or with missing Ct, equal to
the detection limit of 35 (Figure 1). To reduce background noise, we
excluded miRNAs not expressed in at least 90% of samples (Ct = 35),
producing a ﬁnal data set of 123 miRNAs. The mean Ct of the three
endogenous small RNA controls was used as an internal control to
normalize the amount of individual miRNA in each sample. Relative
quantiﬁcation of miRNA expression was determined by the ΔΔCt method
in which expression levels of each normalized miRNA were calculated
relative to a calibrator sample that consisted of a pool of 90 samples; it was
used as the 1 × sample (or 100%), and the relative value of each miRNA
was expressed as an n-fold difference from the calibrator (Figure 1).
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The same preliminary data cleaning and normalization methods were
applied to the subsets of miRNAs selected for validation.
Statistical analysis
Descriptive statistics were performed on all variables. Normally distributed
data are reported as means ± s.d. or frequencies, as appropriate. We used
linear regression models to test the association between urinary Cr and
miRNA expression in both the screening and validation phases. MiRNA
expression, quantiﬁed by relative quantiﬁcation, was log transformed to
achieve a normal distribution.
Multivariate regression analyses, adjusted for age, sex, BMI, smoking
habits and granulocyte percent, were used to evaluate changes in miRNA
expression in association with urinary Cr level on the recruitment day.
Owing to the high number of comparisons made, we took into account a
correction for multiple comparisons based on the false discovery rate (FDR)
control. A threshold of 0.10 was applied on FDR P-value signiﬁcance
(P-FDR) to identify the top miRNAs among the 377 screened. The same
analyses were repeated in the validation phase on the set of miRNAs
selected for conﬁrmation. Multivariate regression models, adjusted for sex,
age, BMI, granulocyte percentage and smoking habits, were also applied to
assess the possible association between conﬁrmed miRNAs and two
selected clinical parameters: A1c and diastolic/systolic BP. Logarithmic
transformations were applied, when appropriate, to achieve normal
distributions of outcome variables in regression models. We conducted a
residual ﬁt analysis to conﬁrm the model ﬁt. All analyses were performed
using SAS 9.3 (SAS Institute, Cary, NC, USA).
Prediction of miRNA targets and pathway analysis
Data from the top 10 miRNA were submitted to the IPA Core for Ingenuity
Pathway Analysis (Ingenuity Systems, Redwood City, CA, USA) to
investigate the signaling and metabolic pathways, molecular networks
and biological processes associated with them. Putative miRNA–mRNA
relationships were identiﬁed with the IPA microRNA Target Filter, based on
a knowledge base of prediction with high-conﬁdence and experimentally
observed relationships from TargetScan, TarBase, miRecords and Ingenuity
Knowledge Base. The resulting target gene lists were analyzed to identify
diseases and biological functions associated with miRNA gene sets.
We ﬁltered the results for CVDs, nutritional diseases and metabolic
diseases, and the resulting target gene list, in addition to nine miRNAs, was
analyzed with IPA core analysis. Functional analysis was carried out to
identify canonical pathways and molecular networks that have been
associated with the mRNA target gene set. The IPA database considers
gene–phenotype associations, molecular interactions, regulatory events
and chemical knowledge to provide a global molecular network. Related
networks were constructed algorithmically based on connectivity. The
statistical signiﬁcance of each biological function was calculated using
Fisher’s exact text with alpha set to 0.05.
RESULTS
Characteristics of study participants and urinary Cr assessment
The main characteristics of the study participants are presented
in Table 1. Brieﬂy, a majority of the participants were women, and a
wide age range (21–75 years) was represented. All subjects had a
BMI 425 kg/m2, and 62.2% were obese (BMI 430 kg/m2). We
observed a wide range of urinary Cr levels (0.05–1.27 μg/l). In
addition, 43.1% of subjects were insulin resistant, and 8.3% of
subjects were diabetic. Hypertension was observed in 33.9% of
subjects.
miRNA expression screening and validation in association with
urinary Cr
After data cleaning, 123 miRNAs were analyzed, according to the
criteria described in the Materials and methods section. In the
screening phase, we identiﬁed 43 miRNAs that were negatively
associated with urinary Cr levels (Po0.05, P-FDRo0.10). Table 2
shows the percentage change of miRNA expression in terms of
relative quantiﬁcation per 1% increment in urinary Cr Ten
candidate miRNAs were chosen for validation, on the basis of
their signiﬁcant P-value and P-FDR. Consistent with the screening
data, nine miRNAs (miR-451, miR-301, miR-15b, miR-21, miR-26a,
miR-362-3p, miR-182, miR-183 and miR-486-3p) were negatively
associated with urinary Cr level, with a P-FDR o0.10 (Table 3). The
mean coefﬁcient of variability of this study was 0.89%.
miRNA associations with clinical parameters
miR-451 expression associated negatively with A1c (Δ%=− 0.06%;
P= 0.0416) (Figure 2a), whereas miR-486-3p expression associated
positively with both diastolic (Δ%=2.11%; P= 0.004; Figure 2b)
and systolic BP (Δ%=3.34%; P= 0.003; Figure 2c). None of the
Figure 1. Data processing workﬂow. Cal, Calibrator; Ct, related cycle threshold; RQ, relative quantiﬁcation; Sam, sample.
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other miRNAs were associated with the examined clinical
parameters (data not shown).
Target gene identiﬁcation and functional analysis
We identiﬁed 4473 mRNAs that were experimentally observed or
highly predicted targets. When the data were ﬁltered for
metabolic and signaling pathways only, we found 1570 mRNA
targets that mapped to several molecular networks. To investi-
gate if the mRNAs targeted by our nine validated urinary
Cr-associated miRNAs (Table 3) were potentially involved in
biological processes connected to obesity and related diseases,
the list was ﬁltered for cardiovascular, nutritional and metabolic
diseases, resulting in 764 genes (Supplementary Table 1). The
number of targeted mRNAs for each miRNA was: miR-451 = 16,
miR-301=164, miR-15b=247, miR-21=77, miR-26a=147, miR-362-
3p=62, miR-182=185, miR-183=80 and 486-3p=111.
To understand the biological functions of the mRNA targets, we
performed IPA’s core analysis, and the top canonical pathways were
molecular mechanisms of cancer (P=7.96×10-61), axonal guidance
signaling (P=2.25×10-47), protein kinase A signaling (P=8.46×
10-43), role of NFAT in cardiac hypertrophy (P=1.13×10-42) and
phosphatase and tensin homolog (PTEN) signaling (P=2.64×10-42).
The top two networks were enriched for nervous system develop-
ment (score: 39) and function, tissue morphology, cell death and
survival and for cardiovascular system development and function,
organismal development and organismal survival (score: 37). We
also investigated the diseases possibly associated in our enrichment
analysis. Table 4 summarizes the top ﬁve diseases, and shows that
CVD and metabolic disease are the most signiﬁcantly involved, with
432 and 391 associated targeted mRNAs, respectively
(Supplementary Tables 2 and 3). In the cardiovascular category,
the lowest P-value was for vascular disease (4.88×10-114) and
highest was for congenital heart disease (2.01×10-33); in the
metabolic category the lowest P-value was for glucose metabolism
disorders (9.80×10-113) and the highest was for non-insulin-
dependent disorders (1.19×10-29; Table 4).
DISCUSSION
To further investigate the mechanisms linking Cr to metabolic and
cardiovascular disorders, we analyzed miRNA expression in
leukocytes from obese subjects in association with urinary Cr,
and examined how altered miRNA expression related to A1c and
diastolic/systolic BP. Obese individuals were chosen for this study
because of their strong susceptibility to diabetes, insulin resistance
and CVD. We identiﬁed and validated a distinct signature of nine
miRNAs in peripheral blood that associated negatively with
urinary Cr and among these only miR-451 was associated with
A1c, suggesting a role for miR-451 in the development of diabetes.
Meanwhile, miR-486-3p was associated with systolic and diastolic
BP, suggesting it may be a factor in CVD risk.
The two most widespread oxidation states of Cr, Cr+3 and Cr+6,
have different mobility and bioavailability, resulting in differential
Table 2. Percentage change of miRNAs expression in proﬁling phase
miRNA Δ% 95% CI Raw P P-FDR
Lower Upper
miR-486-3p −29.6% −43.4% −12.5% 0.002 0.093
miR-21 −39.1% −56.4% −15% 0.005 0.093
miR-362-3p −43.3% −61.4% −16.7% 0.005 0.093
miR-26a −34.6% −51.4% −11.9% 0.007 0.093
miR-15b −38.7% −56.6% −13.5% 0.007 0.093
miR-182 −51.9% −71.3% −19.4% 0.007 0.093
miR-101 −44.1% −63% −15.4% 0.007 0.093
miR-183 −47.8% −67.4% −16.4% 0.008 0.093
miR-301a −45.3% −64.8% −15% 0.009 0.093
miR-451 −28.4% −44.1% −8.3% 0.010 0.093
miR-374a − 42% − 61.3% − 12.9% 0.011 0.093
miR-106b − 32.9% − 50.3% − 9.3% 0.011 0.093
miR-660 − 31.1% − 48.1% − 8.7% 0.012 0.093
miR-598 − 42.8% − 62.7% − 12.2% 0.013 0.093
miR-335 − 34.8% − 53.1% − 9.5% 0.013 0.093
miR-148b − 37.2% − 56% − 10.3% 0.013 0.093
miR-26b − 37.3% − 56.4% − 10% 0.013 0.093
let-7b − 27.9% − 44.2% − 6.8% 0.015 0.093
miR-18a − 38.6% − 58.1% − 9.8% 0.015 0.093
miR-126 − 43.9% − 64.7% − 11% 0.016 0.093
miR-192 − 25.7% − 41.3% − 5.8% 0.017 0.093
miR-22 − 29.1% − 46.3% − 6.4% 0.018 0.093
let-7 g − 35.6% − 54.9% − 8.1% 0.018 0.093
miR-19a − 27.8% − 44.5% − 6% 0.018 0.093
miR-103 − 31.4% − 49.7% − 6.5% 0.020 0.096
miR-142-5p − 32.7% − 51.6% − 6.4% 0.021 0.099
miR-374b − 33.6% − 53.2% − 5.8% 0.024 0.099
miR-106a − 32.1% − 51.4% − 5.3% 0.025 0.099
miR-132 − 29% − 47.1% − 4.6% 0.026 0.099
let-7e − 29.5% − 48% − 4.5% 0.027 0.099
miR-25 − 23.2% − 38.9% − 3.4% 0.027 0.099
miR-17 − 31.7% − 50.9% − 4.9% 0.027 0.099
miR-93 − 30.9% − 50.3% − 4% 0.031 0.099
miR-194 − 25.9% − 43.4% − 3.1% 0.032 0.099
miR-195 − 34.5% − 55.2% − 4.4% 0.032 0.099
miR-532-5p − 25.9% − 43.4% − 3% 0.033 0.099
miR-29c − 33.2% − 53.7% − 3.8% 0.033 0.099
miR-142-3p − 23.8% − 40.3% − 2.6% 0.033 0.099
miR-331-3p − 20.7% − 35.7% − 2.1% 0.034 0.099
miR-130b − 28.3% − 47% − 3% 0.034 0.099
let-7a − 30.5% − 50% − 3.3% 0.034 0.099
miR-340 − 32.9% − 53.3% − 3.6% 0.034 0.099
miR-24 − 23.4% − 39.9% − 2.3% 0.035 0.099
Abbreviations: CI, conﬁdence interval; Cr, chromium; FDR, false discovery
rate; miRNA, microRNA. The miRNA percentage change is expressed per
1% increment of Cr exposure. Models were adjusted for sex, age, BMI,
granulocyte percentage and smoking habits. All miRNAs, Po0.10. The top
10 miRNAs (bold) were selected for validation.
Table 1. Study cohort characteristics (N= 90)
Characteristic NR (proportion) Mean± s.d.
Sex
Men 15 (16.7%)
Women 75 (83.3%)
Age, (years) 51.6± 11.9
BMI, (kg/m2) 32.9± 5.7
Overweight (25≤BMIo30) 34 (37.8%)
Class I obesity (30≤BMIo35) 28 (31.1%)
Class II obesity (35≤BMIo40) 19 (21.1%)
Class III obesity (BMI≥ 40) 9 (10.0%)
Smoke
Never smoked 48 (53.3%)
Former smoker 26 (28.9%)
Current smoker 16 (17.8%)
Blood count
White blood cells (%) 7.0± 2.0
Granulocytes (%) 61.3± 7.6
Monocytes (%) 8.4± 3.2
Lymphocytes (%) 30.4± 7.6
Red blood cells (%) 4.8± 0.5
A1c (mmol/mol) 41.6± 8.4
Chromium, (μg/l) 0.35± 0.24
Diastolic pressure (mmHg) 79.2± 10.2
Systolic pressure (mmHg) 124.8± 16.5
Abbreviations: A1c, glycated hemoglobin; BMI, body mass index; NR,
number. Continuous variable are expressed as mean± s.d. Discrete
variables are expressed as counts (%).
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penetration of biological membranes, possibly explaining their
quite different toxicities. Hexavalent Cr derivatives easily penetrate
cell membranes and are easily absorbed from the gastrointestinal
tract and lungs, whereas trivalent Cr compounds do not traverse
biological membranes well.28 Excretion of Cr occurs primarily via
urine and reﬂects absorption only over the previous 1–2 days. The
measurement of urine Cr concentration by ICP-MS is a well-
established method in elemental analysis, because of its unique
analytical capabilities, and reﬂects the total Cr level (Cr+6 and
Cr3+).29 Only trivalent Cr is an essential mineral; it potentiates
insulin effects in normal glucose metabolism. Cr supplementation
may, therefore, improve systemic insulin sensitivity.30 People with
diabetes may have altered Cr metabolism compared with non-
diabetic subjects,31 perhaps because of hyper-absorption and
excretion of Cr.32,33
Epidemiological studies suggest a link between Cr status and
CVD.12 Guallar et al.13 found that patients who died from coronary
artery disease had signiﬁcantly lower Cr levels in their aortic tissue
than patients who died from accidents. The Cr concentration in
biological samples (scalp hair, blood and urine) is inversely
associated with risk of myocardial infarction (MI).34
Mounting evidence suggests a crucial role of miRNAs in insulin
resistance and β-cell dysfunction, two main features of type 2
diabetes,17 and in the onset and development of CVD.19 The
hypothesis that miRNAs have an important role in metabolic
diseases and CVDs is strengthened by the observation that many
miRNAs perform key roles in critical biological processes that
correlate with urinary Cr levels.35 In our study, miR-451 and miR-15b
were negatively associated with urinary Cr. In addition, we found a
signiﬁcant association between miR-451 expression and A1c levels,
suggesting that miR-451 may be involved in diabetes pathogenesis
because greater increases in A1c indicate worse control of blood
glucose levels.36 Zhang et al.37 showed that miR-451 regulates p38
mitogen-activated protein kinase signaling and suppresses mesan-
gial hypertrophy in early diabetic nephropathy. MiR-451 and
miR-15b, by modulating apoptosis and angiogenesis, are involved
in coronary artery disease38,39 and MI.40,41
Our data show that miR-486-3p is associated with diastolic and
systolic BP regulation, and IPA core analysis identiﬁed cardiac
hypertrophy and PTEN signaling as canonical pathways interacting
with this miRNA. In fact, miR-486-3p has been associated with
systemic ventricular contractility42 and is a critical regulator of
muscle growth. Small et al.43 showed that miR-486-3p targets PTEN
and Foxo1a directly, enhancing the phosphatidylinositide 3-kinase/
protein kinase B (PI3K/AKT) signaling in muscle cells. Overexpression
of miR-486-3p reduces PTEN and Foxo1a protein expression and
enhances PI3K/AKT signaling, eventually leading to muscle hyper-
trophy. PI3K is a known regulator of skeletal muscle hypertrophy
and atrophy.44 The increase of miR-486-3p in the plasma of acute MI
patients may reﬂect an underlying cardiac hypertrophy.45
Our results revealed a Cr-related downregulation in miR-26a and
miR-21 expression; some authors have also found that miR-26a was
downregulated in the sera of patients with acute MI.46 MiR-21
exhibits increased expression in several forms of CVD47 and is
sensitive to high-concentration glucose treatment in macrophages,
providing resistance to apoptosis induced by high glucose
concentrations via programmed cell death 4 (PDCD4) regulation.48
MiR-182 and miR-183 constitute a well-known miRNA cluster,
located on chromosome 7, which is involved in insulin signaling
and energy metabolism. Xu and Wong49 provided experimental
evidence indicating that this miRNA cluster, miR-183-96-182,
targets Irs1, Rasa1 and Grb2, the products of which are all in the
insulin signaling pathway. In our obese subjects, two components
of this cluster (miR-182 and miR-183) were signiﬁcantly related to
urinary Cr, suggesting their correlation with the insulin pathway.
We also found that miR-301a and miR-362 were negatively
associated with urinary Cr, and our IPA core analysis indicated that
the PTEN signaling pathway was the top canonical pathway
related to expression of these miRNAs. Mir-301a and miR-362 are
involved in the NF-kB (nuclear factor kappa light-chain enhancer
of B cells) and insulin pathways. MiR-301a, which modulates Kv4.2
(potassium voltage-gated channel subfamily D2) by binding to its
3'-UTR, is downregulated in the hearts of diabetes patients,
indicating the direct association of mir-301a with diabetes.50
MiR-301a regulates IL-6-induced insulin resistance by direct
regulation of PTEN expression.51
Elevation of miR-451 in red blood cells may affect its
quantiﬁcation in leukocytes,52 but a strength of our study was
the use of the PAXgene Blood System, which allows complete red
blood cells lysis and loss before miRNA isolation. Another strength
of this study was the use of a non-targeted, exploratory approach
to select candidate miRNAs. We chose to use a real-time PCR
approach for miRNA expression analysis because its provides
sufﬁciently high precision and sensitivity to detect closely related
miRNAs, which may differ in sequence by only a single base.53
Furthermore, to limit false positives in the detection of differen-
tially expressed miRNAs, we used restrictive statistical signiﬁcance
cutoffs.
Our population is composed essentially of female gender, but a
recent study54 showed that sex seemed to have a weak effect on
the miRNA levels. With the aim of taking into account the different
distribution of males and females, and different obesity levels in
our population we decided to ‘a priori’ adjust all models for sex
and BMI. Also we tested in all multivariate models the inclusion of
the interaction with sex or BMI. In none of our models, the
interaction was signiﬁcant. These results suggest that sex and BMI
are not acting as effect modiﬁers of our analysis.
In our study population, the mean urinary Cr level was higher
than that found in the general Italian population55 and was higher
Table 3. Percentage change of miRNA expression in validation phase
miRNA Δ% 95% CI P-value P-FDR
Lower Upper
miR-451 − 73.2 − 85.1 − 51.6 o0.001 o0.001
miR-301 − 95.3 − 98.9 − 78.8 0.000 0.001
miR-15b − 83.5 − 94.0 − 54.5 0.001 0.003
miR-21 − 80.3 − 92.5 − 48.6 0.001 0.004
miR-26a − 75.7 − 89.7 − 42.6 0.002 0.004
miR-362-3p − 88.7 − 97.1 − 56.7 0.002 0.004
miR-182 − 74.0 − 89.5 − 35.5 0.005 0.007
miR-183 − 77.8 − 94.9 − 4.0 0.048 0.060
miR-486-3p − 74.8 − 94.1 6.8 0.065 0.072
miR-101 − 30.5 − 69.3 57.5 0.387 0.387
Abbreviations: CI, conﬁdence interval; Cr, chromium; FDR, false discovery
rate; miRNA, microRNA. The miRNA percentage change is expressed per
1% increment of Cr exposure in validation. Models were adjusted for sex,
age, BMI, granulocyte percentage and smoking habits.
Table 4. IPA core analysis: top diseases/disorders with maximum and
minimum P-values
Disease or disorder P-value # mRNA
CVD 2.01 × 10-33 - 4.88 × 10-114 432
Metabolic disease 1.19 × 10-29 - 9.80 × 10-113 391
Endocrine system disease 1.19× 10-29 - 1.89 × 10-83 246
Gastrointestinal disease 1.19× 10-29 - 1.89 × 10-83 630
Inﬂammatory disease 1.89 × 10-31 - 1.75 ×10-76 315
Abbreviation: CVD, cardiovascular disease. # mRNA, no. individual mRNA
species involved in the indicated pathways.
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than the mean concentration recommended by the Institute of
Medicine of the National Research Council (0.22 μg/l). This ﬁnding
could be explained by the high percentage of people with insulin
resistance in the study. We used one of the most robust
commercially available ICP-MS instruments, which provided many
advantages, including elemental speciﬁcity and high measure-
ment sensitivity over a wide linear dynamic range.56 One
limitation of our study was the lack of Cr speciation; to achieve
Cr speciation, ICP-MS analysis would have to be coupled with high
performance liquid chromatography.57 In addition, from the initial
list of 43 miRNAs, we chose to validate only 10 based on their
P-FDR values; it is possible that we may have excluded some
relevant miRNAs involved in Cr metabolism. We did adjust for
potential confounding variables in our analysis. Moreover, the
relatively small sample size may have limited our ability to detect
signiﬁcant effects, and larger studies are needed to conﬁrm our
ﬁndings.
CONCLUSION
Several circulating miRNAs are considered emerging blood
biomarkers for many diseases because they are stable molecules,
tissue speciﬁc, evolutionarily conserved and easy to detect.
Changes in miR-451 and miR-486-3p expression, in association
with urinary Cr, and their relation with A1c and BP, respectively,
are helpful for identifying mechanisms linking Cr with metabolic
diseases and CVDs.
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